Navigation Links
Simulation study may help Parkinson's patients retain driving skills
Date:2/1/2010

AUGUSTA, Ga. In a first-of-its-kind study, Medical College of Georgia researchers are testing whether simulation driving can reduce Parkinson's patients' threefold increased risk of car accidents.

Drivers with Parkinson's disease are three times more likely to have a car accident than healthy drivers because of cognitive, motor and visuospatial impairments.

Previous studies show that mind-challenging activities improve retention of cognitive capabilities.

"The question is how long can a patient retain the benefit of the retrained skills before it's eroded by this progressive disease?" says Dr. Abiodun Akinwuntan, assistant professor of physical therapy and neurology in the Schools of Allied Health Sciences and Medicine and director of MCG's Driving Simulation Lab. He expects training will improve and slow the degeneration of driving skills, enabling patients to stay on the road longer than Parkinson's patients without the training.

Funded by a $10,000 grant from the Augusta Chapter of the National Parkinson Foundation, researchers will study 30 local patients with stage two or three Parkinson's disease.

Participants will take cognition tests, a simulator-based driving test and an on-road driving test before and after the five-week training period.

The simulation training consists of 10 one-hour sessions in a car with driving scenarios projected on three life-sized screens. Participants will "drive" as they would in real life to navigate the scenarios, which simulate local workday traffic.

The scenarios test skills including visuospatial, visual attention and memory, reaction time, hazard perception and executive function. The program documents the participants' number of lane edge crossings, speeding tickets, traffic light violations, accidents and reaction time.

The study will determine if simulation training improves driving and if the improvement translates to on-road testing.

"Parkinson's disease causes patients to lose automatic abilities, including those associated with driving," says Dr. John Morgan, associate professor of neurology in the School of Medicine and director of the MCG Movement Disorders Program's National Parkinson Foundation Center of Excellence. "The old adage, 'You can't walk and chew gum at the same time,' applies in Parkinson's, and driving involves multiple tasks, so that ability is impacted."

Nearly 70 percent of Parkinson's patients eventually stop driving because of symptoms including freezing of movement, lack of coordination, slow reaction time, cognitive decline and/or medication side-effects such as drowsiness. While most patients drive until the disease reaches stage three, which is characterized by symptoms on both sides of the body and some balance impairment, 18 percent give up driving long before safety becomes a factor, Dr. Akinwuntan says.

"Driving has become such a fundamental daily activity that we often underestimate the influence it has on decisions such as the location of our homes, clothes we wear, activities we engage in and social functions we attend," Dr. Akinwuntan says.

Driving not only enhances independence, it fosters other cognitive tasks, such as checking items off of a grocery list after driving to the store.

"Perhaps patients engaged in such an intervention will continue driving two or three years longer than those without training," Dr. Akinwuntan says. Study findings also may apply to other cognition-impaired patients, such as those with traumatic brain injury or Alzheimer's disease.


'/>"/>

Contact: Paula Hinely
phinely@mcg.edu
706-721-3646
Medical College of Georgia
Source:Eurekalert  

Related biology news :

1. Simulation reveals how body repairs balance after damage
2. Virtual human in HIV drug simulation
3. Computer simulations point to key molecular basis of cystic fibrosis
4. Are existing large-scale simulations of water dynamics wrong?
5. Actor-robots staff part of new $5M simulation training center
6. Simulations help explain fast water transport in nanotubes
7. Rhode Island Hospital simulation center examines benefits and applications of medical simulation
8. ORNL supercomputer simulation wins prize for fastest-running science application
9. New open-source software permits faster desktop computer simulations of molecular motion
10. New simulation shows consequences of a world without Earths natural sunscreen
11. Computer simulations explain the limitations of working memory
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Simulation study may help Parkinson's patients retain driving skills
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to its ... meaningful advances worldwide, The Japan Prize Foundation today ... who have pushed the envelope in their respective ... Communication. Three scientists are being recognized with the ... that not only contribute to the advancement of ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
(Date:2/16/2017)... and NEW YORK , Feb. 16, ... completion of their $7M Series B financing, adding an ... the $3.5M led by Mesa Verde Venture Partners and ... resources will be directed towards further accelerating commercial adoption ... comprehensive genomic profiling test and expanding the Paradigm cancer ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. ... Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung ... Klasse führenden Plattform für die Entdeckung monoklonaler Antikörper. ... ihr neuartiges chimäres Gensegmentdesign aus, das Janssen ... humanen Antikörpern bietet und das für die schelle ...
(Date:2/15/2017)... -- Windtree Therapeutics, Inc. (Nasdaq: WINT ), ... therapies for respiratory diseases, will host a conference call ... EST on Thursday, February 16, 2017 to provide updates ... announced closing of a $10.5 million private offering and ... in the live call and take part in the ...
Breaking Biology Technology: